130 related articles for article (PubMed ID: 12111120)
1. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
Berd D; Sato T; Mastrangelo MJ
Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
[TBL] [Abstract][Full Text] [Related]
2. Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine.
Berd D
Vaccine; 2003 Jan; 21(7-8):795-7. PubMed ID: 12531362
[TBL] [Abstract][Full Text] [Related]
3. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
Berd D; Sato T; Cohn H; Maguire HC; Mastrangelo MJ
Int J Cancer; 2001 Nov; 94(4):531-9. PubMed ID: 11745440
[TBL] [Abstract][Full Text] [Related]
5. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
[TBL] [Abstract][Full Text] [Related]
6. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
Berd D; Maguire HC; Schuchter LM; Hamilton R; Hauck WW; Sato T; Mastrangelo MJ
J Clin Oncol; 1997 Jun; 15(6):2359-70. PubMed ID: 9196151
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Berd D; Maguire HC; McCue P; Mastrangelo MJ
J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
[TBL] [Abstract][Full Text] [Related]
8. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
9. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Opin Biol Ther; 2002 Mar; 2(3):335-42. PubMed ID: 11890872
[TBL] [Abstract][Full Text] [Related]
10. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
11. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
Dillman RO; Beutel LD; Barth NM; de Leon C; O'Connor AA; DePriest C; Nayak SK
Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
[TBL] [Abstract][Full Text] [Related]
12. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
13. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.
Berd D; Maguire HC; Mastrangelo MJ
Cancer Res; 1986 May; 46(5):2572-7. PubMed ID: 3697996
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
15. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
Lotem M; Peretz T; Drize O; Gimmon Z; Ad El D; Weitzen R; Goldberg H; Ben David I; Prus D; Hamburger T; Shiloni E
Br J Cancer; 2002 May; 86(10):1534-9. PubMed ID: 12085200
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
[TBL] [Abstract][Full Text] [Related]
17. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
Baars A; Claessen AM; van den Eertwegh AJ; Gall HE; Stam AG; Meijer S; Giaccone G; Meijer CJ; Scheper RJ; Wagstaff J; Vermorken JB; Pinedo HM
Ann Oncol; 2000 Aug; 11(8):965-70. PubMed ID: 11038032
[TBL] [Abstract][Full Text] [Related]
18. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.
Mahipal A; Terai M; Berd D; Chervoneva I; Patel K; Mastrangelo MJ; Sato T
Cancer Immunol Immunother; 2011 Jul; 60(7):1039-45. PubMed ID: 21519827
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.
Lotem M; Shiloni E; Pappo I; Drize O; Hamburger T; Weitzen R; Isacson R; Kaduri L; Merims S; Frankenburg S; Peretz T
Br J Cancer; 2004 Feb; 90(4):773-80. PubMed ID: 14970852
[TBL] [Abstract][Full Text] [Related]
20. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC
Semin Oncol; 1998 Dec; 25(6):646-53. PubMed ID: 9865679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
